PRZOOM - /newswire/ -
Malden, MA, United States, 2010/01/12 - The distribution agreement provides Almog Diagnostic with the rights to distribute Kollodis’ cell culture products in Israel on a non-exclusive basis.
Kollodis BioSciences, Inc. announced today that it has entered into a Distribution Agreement with Almog Diagnostic for the distribution of Kollodis BioSciences, Inc.'s MAPTrix® ECM line of products for cell culture and related applications.
Dr. Louis M. Scarmoutzos, President & CEO of Kollodis BioSciences, Inc., stated, "We are absolutely delighted with this distribution agreement. Almog Diagnostic is a well-established and reputable partner for bringing Kollodis' research products to the Israel market. With the assistance of Almog Diagnostic, we are happy to offer our products and service to our new customers in Israel. Almog Diagnostic has an excellent reputation with their customers and suppliers. And we look forward to a lasting and fruitful relationship with them."
Among the Mussel Adhesive Protein based matrix (MAPTrix®) ECM line of products are reagents with genetically incorporated bioactive peptides (recognition peptides) that mimic the extracellular matrix (ECM) activity of collagen, fibronectin, laminin, and vitronectin proteins. The bioactive peptide mimics the extracellular matrix (ECM) protein and provides for cell attachment, spreading and growth. The mussel adhesive protein confers biocompatible adhesion to a wide variety of surfaces.
A MAPTrix® surface coating application promotes cell plating efficiency, improves morphology, and enhances cell proliferation under serum-free conditions in primary cell cultures such as hepatocytes or neural cells.
About Almog Diagnostic Ltd
Almog is offering a wide range of immunological products for the medical diagnostic and the research market.
About Kollodis BioSciences, Inc.
Kollodis BioSciences, Inc. (kollodis.com) has successfully developed a proprietary recombinant protein expression system for the large scale production of various mussel adhesive proteins (MAP). Kollodis is developing MAP-based smart biomaterials for biotech, medical and industrial applications. The Company's proprietary and patented MAPTrix® platform technology recombinantly incorporates bioactive peptides into a mussel adhesive protein (MAP) for cell culture and related applications. Additional information is available on the Company's website.